Quotient, CytoAgents develop COVID-19 cytokine storm treatment

By The Science Advisory Board staff writers

April 28, 2020 -- A new collaboration between Quotient Sciences and CytoAgents will accelerate the development of a lead COVID-19 drug candidate to human clinical trials, the companies announced.

The partnership will focus on rapid development of CytoAgents' lead COVID-19 drug candidate, GP1681, for phase I and II trials in 2020. The candidate is a small-molecule inhibitor of cytokine release in activated human immune cells that shows potential in blocking the "cytokine storms" associated with severe illness in COVID-19 cases.

Under the agreement, CytoAgents will use Quotient's formulation and manufacturing expertise to develop and rapidly supply drug product for clinical trials. Quotient will also work to develop a scalable solid oral dosage form for larger patient trials. The program will be conducted at Quotient's specialized drug handling and containment facility in Pennsylvania.

Theravance's Janus kinase inhibitor enters phase I for ARDS
Biopharmaceutical company Theravance Biopharma has begun a phase I study in the U.K. for a drug to help prevent the development of acute respiratory distress...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter